Tyra Biosciences, a clinical-stage biotech company specializing in precision medicines targeting FGFR biology, announced its participation in two major investor conferences in November 2026: the Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference. These events will feature one-on-one meetings and a hybrid presentation, including a live webcast accessible on Tyra's website. The company is advancing several clinical-stage drug candidates, including dabogratinib for urothelial cancer and achondroplasia, and other FGFR inhibitors for liver and bile duct cancers. These presentations aim to update investors on Tyra's pipeline progress and strategic direction.
Tyra Biosciences' upcoming participation in investor conferences is noted alongside Pluang's health sector data. For readers following health stocks, here is Pluang's market snapshot as of Nov 06, 2026 04:11 WIB: out of 150 priced US health-sector stocks, 16 rose and 134 fell. Notable movers include ADMA Biologics Inc with a 26.34% gain, Natera Inc. down 23.32%, and Guardant Health Inc. down 23.00%.
Loma Negra, Argentina's leading cement producer, reported a net profit of Ps. 14.5 billion for Q3 2026, reversing a loss of Ps. 11.5 billion in the same period last year. Despite a 3.2% decline in net sales mainly due to weaker concrete segment reven...
Saul Centers reported Q3 2026 revenue of $78.4 million, up from $72 million a year earlier, driven by higher rents and property leasing. However, net income declined to $12.6 million from $14 million, mainly due to $3.7 million in costs related to th...
Shares of major cybersecurity companies like CrowdStrike, Okta, Cloudflare, and Palo Alto Networks dropped sharply on Thursday, falling 8-10% amid a broad tech market selloff. These stocks, once seen as resilient and benefiting from AI growth, faced ...
Shoulder Innovations, a medical tech company focused on shoulder surgical care, reported a 38% increase in Q3 2026 revenue to $16.2 million, driven by higher implant sales and prices. The company raised its 2026 revenue guidance to $68-$70 million, r...
Autoscope Technologies Corporation reported a net income of $366,000 for Q3 2026, a 275% increase from a net loss in the same period last year, driven by higher royalties and lower operating expenses. The company declared a quarterly dividend of $0.1...
